New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For AZN;MYL;TEVA From The Last 14 Days
Check below for free stories on AZN;MYL;TEVA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | all recent news | >>
April 16, 2014
16:16 EDTMYLMylan launches first generic Ortho Evra patch
Subscribe for More Information
10:00 EDTTEVAOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: A10 Networks (ATEN) initiated with a Buy at BofA/Merrill... Actavis (ACT) initiated with a Buy at Sterne Agee... Allergan (AGN) initiated with a Buy at Sterne Agee... Autohome (ATHM) initiated with a Neutral at Credit Suisse... BitAuto (BITA) initiated with an Outperform at Credit Suisse... Centene (CNC) initiated with a Neutral at UBS... Endo International (ENDP) initiated with a Buy at Sterne Agee... FS Investment (FSIC) initiated with an Overweight at Evercore... Hertz (HTZ) initiated with a Buy at Gabelli... Hilton (HLT) initiated with a Hold at Jefferies... Hospira (HSP) initiated with a Neutral at Sterne Agee... ImmunoGen (IMGN) initiated with a Buy at Canaccord... Impax (IPXL) initiated with a Neutral at Sterne Agee... Imperva (IMPV) assumed with a Neutral at Wedbush... Ingredion (INGR) initiated with an Outperform at Credit Suisse... Laredo Petroleum (LPI) initiated with an Outperform at RW Baird... Lpath (LPTN) initiated with a Buy at Canaccord... MediWound (MDWD) initiated with an Outperform at Oppenheimer... Medivation (MDVN) initiated with a Hold at Canaccord... NPS Pharmaceuticals (NPSP) assumed with a Buy at Canaccord... Nimble Storage (NMBL) initiated with a Market Perform at Raymond James... Regeneron (REGN) initiated with a Buy at Canaccord... Salix (SLXP) initiated with a Buy at Sterne Agee... Sibanye Gold (SBGL) initiated with an Outperform at Imperial Capital... Teva (TEVA) initiated with a Neutral at Sterne Agee... Wipro (WIT) assumed with a Hold at Jefferies.
07:00 EDTTEVATeva initiated with a Neutral at Sterne Agee
Subscribe for More Information
April 15, 2014
12:26 EDTTEVATeva announces launch of generic Lunesta tablets in U.S.
Subscribe for More Information
10:21 EDTMYLMylan announces settlement agreement for first-to-file Generess
Subscribe for More Information
10:10 EDTMYLMylan launches generic Lunesta tablets
Subscribe for More Information
08:19 EDTAZNLeerink's pharma and biotech analysts hold an analyst/industry conference call
Subscribe for More Information
08:07 EDTMYLActavis announces agreement related to Generess FE patent challenge litigation
Actavis (ACT) announced that it has entered into an agreement with Mylan (MYL) and Famy Care to settle all outstanding patent litigation related to Mylan's generic version of Generess. Under the terms of the agreement, Actavis will grant Mylan a license to market its generic version of GeneressŪ FE under its pending Abbreviated New Drug Application beginning on April 1, 2015. Alternatively, Mylan will be permitted to launch an authorized generic version of Actavis' product beginning on October 1, 2015. Other terms of the settlement were not disclosed. Actavis remains in litigation with Lupin Ltd in connection with Lupin's pending ANDA for a generic version of Generess.
08:06 EDTMYLProsonix, Mylan enter licensing deal for generic version of Flixotide, Flovent
Subscribe for More Information
06:32 EDTAZNPatients paying much more for specialty drugs, NY Times says
The amount that patients with certain diseases must pay for specialty drugs has increased significantly, a research firm reported, according to The New York Times. Meanwhile, consumers' use of health care increased in 2013 for the firm time in three years, the newspaper quoted the firm, the IMS Institute for Healthcare Informatics, as saying. Publicly traded drug makers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded health insurers include AMERIGROUP (AGP), Aetna (AET), Centene (CNC), Cigna (CI), Health Net (HNT), Healthspring (HS), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH), WellCare (WCG) and WellPoint (WLP).Reference Link
April 11, 2014
11:50 EDTMYLStocks with call strike movement; TNA MYL
Subscribe for More Information
10:30 EDTMYLActavis and Mylan shares recommended at Bernstein
07:31 EDTMYLMylan confirms judge enforces agreement with Endo regarding generic Frova
Subscribe for More Information
April 9, 2014
05:57 EDTMYLMylan implied volatility of 47 at upper end of index mean range
April 8, 2014
11:03 EDTAZNPiper Jaffray's biopharm analyst holds an analyst/industry conference call
Biopharm Analyst Schimmer discusses PCSK9 Inhibitors and other atherosclerosis approaches on an Analyst/Industry conference call. Relevant companies AEGR, ALNY, AMGN, ARNA, AZN, BMY, CBST, LLY, ESPR, GSK, ICPT, ISIS, MNKD, MRK, OREX, PFE, REGN, RHHBY, SNY and VVUS may be included on the Analyst/Industry conference call to be held on April 10 at 3 pm.
08:46 EDTTEVATeva announces first approval, launch of generic Lovaza capsules in the U.S.
Teva (TEVA) announces the approval of the generic equivalent to Lovaza in the United States. Teva believes it is first-to-file and thus far is the only company to receive an approval from FDA. Teva plans to commence shipping immediately. Lovaza Capsules, marketed by GlaxoSmithKline (GSK), had annual sales of approximately $1.1B in the United States, according to IMS data as of December 2013.
07:56 EDTMYLMylan volatility elevated at 42
Subscribe for More Information
April 7, 2014
16:34 EDTAZNMyriad Genetics submits premarket approval to FDA for BRACAnalysis
Subscribe for More Information
14:09 EDTTEVASun Pharmaceutical agrees to acquire generic drugmaker Ranbaxy
Subscribe for More Information
07:27 EDTAZNAmerican Association of Cancer Research to hold annual meeting
Subscribe for More Information
05:48 EDTAZNMyriad Genetics submits premarket approval to FDA for BRACAnalysis
Subscribe for More Information
April 4, 2014
12:09 EDTMYLOn The Fly: Midday Wrap
Subscribe for More Information
10:45 EDTTEVA, MYLMylan rises despite Meda rejecting takeover offer
Mylan (MYL) shares are higher this morning following a Financial Times report of its desire to buy Swedish rival Meda. Subsequent to the story being published, Meda confirmed it had been in talks with Mylan but rejected the company's takeover offer. WHAT'S NEW: The Financial Times reported that Mylan was considering buying Meda, a Swedish drugmaker, in a deal that would create a $23B+ pharmaceuticals business. Mylan reportedly hired advisers to put a deal together for Meda, and though the value of a deal was not noted, sources said Mylan was likely to pay a "significant" premium to Meda's market value, which was $4.5B at the end of trading on Thursday. Mylan's market value currently stands at $18.5B. A combination of the drugmakers would create a company with annual revenues of around $9B, the FT said, noting that would be half the size of generic drug rival Teva (TEVA). WHAT'S NOTABLE: Meda's board of directors confirmed that it was contacted by Mylan regarding a proposal to merge the companies, but the board decided to reject the proposal. Meda said all discussions between the company and Mylan have been terminated "without further actions." ANALYST REACTION: Citigroup upgraded Mylan to Buy from Neutral and raised its price target on the stock to $61 from $52 this morning. The firm cited potential operational and tax benefits from an acquisition of Meda, stating that in addition to expanding Mylan's geographic presence, the deal would increase its presence in specialty, OTC and branded generics. OTHER NEWS: Mylan sued Celgene (CELG) to block that company's efforts to keep generic versions of Revlimid and Thalomid off the market, Reuters reported. PRICE ACTION: Mylan shares are up $2.98, or 5.98%, to $52.84 in mid-morning trading.
10:02 EDTMYLOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:13 EDTMYLOn The Fly: Pre-market Movers
HIGHER: Mylan (MYL), up 6.8% after report of desire to buy Swedish rival Meda, which confirmed it had been in talks with Mylan but rejected the company's takeover offer. Shares of Mylan were also upgraded to Buy this morning at Citigroup... Mercury Systems (MRCY), up 8.8% after Reuters said Boeing (BA) is considering a takeover bid of the supplier..Micron (MU), up 3% after reporting earnings and revenue that topped expectations... Align (ALGN), up 6% after winning patent case against ClearCorrect... GameStop (GME), up 2.8% following upgrade at BofA Merrill Lynch... Potbelly (PBPB), up 4.6% after upgrade at William Blair.... SYNNEX (SNX), up 18.5% after earnings report. LOWER: CarMax (KMX), down 3.3% after reporting earnings and revenue that fell below expectations... Halozyme (HALO), down 33% after announcing temporary halt of Phase 2 trial enrollment for PEGPH20... Ocean Power (OPTT), down 15% after 3.8M share Spot Secondary priced at $3.10.
09:07 EDTMYLMylan off highs, shares still up 5% after Meda ends takeover talks
Subscribe for More Information
09:06 EDTMYLMeda ends talks with Mylan, rejects takeover proposal
Subscribe for More Information
09:02 EDTMYLMeda says 'decided to reject' proposal from Mylan
09:00 EDTMYLMylan rises 10.7%
Subscribe for More Information
08:46 EDTMYLMylan upgraded to Buy from Neutral at Citigroup
Citigroup upgraded Mylan to Buy citing potential operational and tax benefits from an acquisition of Swedish-based Meda. Mylan is in preliminary talks to acquire Meda, according to the Financial Times. Citi raised its price target for shares to $61 from $52.
08:39 EDTMYLMylan upgraded to Buy from Neutral at Citigroup
Subscribe for More Information
07:45 EDTMYLMylan volatility expected to move on looking at buying Swedish drug maker Meda
Subscribe for More Information
06:49 EDTMYLMylan sues Celgene for blocking Thalomid, Revlimid generics, Reuters says
Subscribe for More Information
06:44 EDTMYLMeda chairman says firm had preliminary discussions with Mylan, Reuters says
Subscribe for More Information
06:08 EDTMYLMylan eyes takeover of Swedish rival Meda, FT reports
Subscribe for More Information
April 3, 2014
14:30 EDTTEVA, MYLMylan says USPTO rejects Teva '808 patent reissue application on Copaxone
Subscribe for More Information
14:28 EDTTEVA, MYLMylan says USPTO rejects Teva '808 patent reissue application on Copaxone
Subscribe for More Information
06:04 EDTMYLMylan implied volatility of 44 at upper end of index mean range
April 2, 2014
11:48 EDTTEVATeva price target raised to $66 from $57 at Standpoint Research
Subscribe for More Information
11:14 EDTMYLOptions with increasing implied volatility: ATHN ISRG MYL
<< 1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use